Erratum: Imaging gene delivery in a mouse model of congenital neuronal ceroid lipofuscinosis (Gene Therapy (2011) 18 (1173-1178) DOI: 10.1038/gt.2011.118);Imaging gene delivery in a mouse model of congenital neuronal ceroid lipofuscinosis

Gene Therapy

Volumn 18, Issue 12, 2011, Pages 1173-1178

  Pike, L S ^a   Tannous, B A ^a   Deliolanis, N C ^b   Hsich, G ^a,c   Morse, D ^a   Tung, C H ^a,d   Sena Esteves, M ^a,e   Breakefield, X O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c LERNER RESEARCH INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

AAV; cathepsin D; central nervous system; fluorescence; lysosomal storage disease; neurologic disease

Indexed keywords

CATHEPSIN D; LIPOFUSCIN; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGENITAL NEURONAL CEROID LIPOFUSCINOSIS; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME REPLACEMENT; EX VIVO STUDY; GENE TARGETING; GENE THERAPY; KNOCKOUT MOUSE; LIFESPAN; MOLECULAR IMAGING; MOUSE; NEAR INFRARED SPECTROSCOPY; NEURONAL CEROID LIPOFUSCINOSIS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT INDICATION;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS;

EID: 83255187260     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.74     Document Type: Erratum

References (53)

1. Hodges BL, Cheng SH. Cell and gene-based therapies for the lysosomal storage diseases. Curr Gene Ther 2006; 6: 227-241.
2. Vellodi A. Lysosomal storage disorders. Br J Haematol 2005; 128: 413-431. (Pubitemid 40283160)
3. Fernandes Filho JA, Shapiro BE. Tay-Sachs disease. Arch Neurol 2004; 61: 1466-1468. (Pubitemid 39202235)
4. Mole SE, Williams RE, Goebel HH. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics 2005; 6: 107-126. (Pubitemid 41396987)
5. Siintola E, Partanen S, Stromme P, Haapanen A, Haltia M, Maehlen J et al. Cathepsin D deficiency underlies congenital human neuronal ceroid- lipofuscinosis. Brain 2006; 129: 1438-1445. (Pubitemid 43999376)
6. Steinfeld R, Reinhardt K, Schreiber K, Hillebrand M, Kraetzner R, Bruck W et al. Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet 2006; 78: 988-998. (Pubitemid 43787690)
7. Whitaker JN, Rhodes RH. The distribution of cathepsin D in rat tissues determined by immunocytochemistry. Am J Anat 1983; 166: 417-428. (Pubitemid 13122045)
8. Reid WA, Valler MJ, Kay J. Immunolocalization of cathepsin D in normal and neoplastic human tissues. J Clin Pathol 1986; 39: 1323-1330. (Pubitemid 17223336)
9. Palmer DN, Husbands DR, Winter PJ, Blunt JW, Jolly RD. Ceroid lipofuscinosis in sheep. I. Bis(monoacylglycero)phosphate, dolichol, ubiquinone, phospholipids, fatty acids, and fluorescence in liver lipopigment lipids. J Biol Chem 1986; 26: 1766-1772. (Pubitemid 17205011)
10. Awano T, Katz ML, O'Brien DP, Taylor JF, Evans J, Khan S et al. A mutation in the cathepsin D gene (CTSD) in American bulldogs with neuronal ceroid lipofuscinosis. Mol Genet Metab 2006; 87: 341-348.
11. Drogemuller C, Wohlke A, Distl O. Characterization of candidate genes for neuronal ceroid lipofuscinosis in dog. J Hered 2005; 96: 735-738. (Pubitemid 41752428)
12. Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J 1995; 14: 3599-3608.
13. Koike M, Nakanishi H, Saftig P, Ezaki J, Isahara K, Ohsawa Y et al. Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J Neurosci 2000; 20: 6898-6906.
14. Koike M, Shibata M, Waguri S, Yoshimura K, Tanida I, Kominami E et al. Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroidlipofuscinoses (Batten disease). Am J Pathol 2005; 167: 1713-1728. (Pubitemid 41713322)
15. Sands MS, Davidson BL. Gene therapy for lysosomal storage diseases. Mol Ther 2006; 13: 839-849.
16. Schiffmann R. Therapeutic approaches for neuronopathic lysosomal storage disorders. J Inherit Metab Dis 2010; 33: 373-379.
17. Kroll RA, Neuwald EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998; 42: 1082-1099.
18. Pohlmann R, Boeker MW, von Figura K. The two mannose 6-phosphate receptors transport distinct complements of lysosomal proteins. J Biol Chem 1995; 270: 27311-27318.
19. McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006; 8: 577-588. (Pubitemid 43827251)
20. Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, Stieg P et al. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther 2004; 15: 1131-1154. (Pubitemid 39552294)
21. Griffey M, Bible E, Vogler C, Levy B, Gupta P, Cooper J et al. Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile. Neurobiol Dis 2004; 16: 360-369. (Pubitemid 38757317)
22. Wong AM, Rahim AA, Waddington SN, Cooper JD. Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis. Biochem Soc Trans 2010; 38: 1484-1488.
23. Shah K, Jacobs A, Breakefield XO, Weissleder R. Molecular imaging of gene therapy for cancer. Gene Therapy 2004; 11: 1175-1187. (Pubitemid 39136781)
24. Funovics M, Weissleder R, Tung CH. Protease sensors for bioimaging. Anal Bioanal Chem 2003; 377: 956-963. (Pubitemid 40877826)
25. Weissleder R, Tung CH, Mahmood U, Bogdanov AJ. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999; 17: 375-378. (Pubitemid 29166041)
26. Tung CH, Mahmood U, Bredow S, Weissleder R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res 2000; 60: 4953-4958.
27. Shah K, Tung CH, Chang CH, Slootweg E, O'Loughlin T, Breakefield XO et al. In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Res 2004; 64: 273-278. (Pubitemid 38120261)
28. Bremer C, Tung CH, Weissleder R. Molecular imaging of MMP expression and therapeutic MMP inhibition. Acad Radiol 2002; 2: S314-S315. (Pubitemid 34857705)
29. Messerli SM, Prabhakar S, Tang Y, Shah K, Cortes ML, Murthy V et al. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia 2004; 6: 95-105. (Pubitemid 38544597)
30. Pham W, Weissleder R, Tung CH. An azulene dimer as a near-infrared quencher. Angew Chem Int Ed Engl 2002; 41: 3659-3662. (Pubitemid 35190479)
31. Rijinboutt S, Stoorvogel W, Geuze HJ, Strous GJ. Identification of subcellular compartments involved in biosynthetic processing of cathepsin d. J Biol Chem 1992; 267: 15665-15672.
32. Broekman ML, Comer LA, Hyman BT, Sena-Esteves M. Adeno-associated virus vectors serotyped with AAV8 capsids are more efficient than AAV-1 or-2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 2006; 138: 501-510. (Pubitemid 43255560)
33. Broekman ML, Baek RC, Comer LA, Fernandez JL, Seyfried TN, Sena-Esteves M. Complete correction of enzymatic deficiency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery. Mol Ther 2007; 15: 30-37. (Pubitemid 46043646)
34. Mahmood U, Tung CH, Bogdanov AJ, Weissleder R. Near-infrared optical imaging of protease activity for tumor detection. Radiology 1999; 213: 866-870.
35. Ntziachristos V, Turner G, Dunham J, Windsor S, Soubret A, Ripoll J et al. Planar fluorescence imaging using normalized data. J Biomed Opt 2005; 10: 064007.
36. Haller J, Hyde D, Deliolanis N, de Kleine R, Niedre M, Ntziachristos VJ. Visualization of pulmonary inflammation using noninvasive fluorescence molecular imaging. Appl Physiol 2008; 104: 795-802. (Pubitemid 351468809)
37. Okamura N,Mori M, Furumoto S, Yoshikawa T, Harada R, Ito S et al. In vivo detection of amyloid plaques in the mouse brain using the near-infrared fluorescence probe THK-265. J Alzherimers Dis 2011; 23: 37-48.
38. Klohs J, Baeva N, Steinbrink J, Bourayou R, Boettcher C, Royl G et al. In vivo nearinfrared fluorescence imaging of matrix metalloproteinase activity after cerebral ischemia. J Cereb Blood Flow Metab 2009; 29: 1284-1292.
39. Passini MA, Lee EB, Heuer GG, Wolfe JH. Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci 2002; 22: 6437-6446. (Pubitemid 35386400)
40. Cearley CN, Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 2007; 27: 9928-9940. (Pubitemid 47404014)
41. Passini MA, Watson DJ, Vite CH, Landsburg DJ, Peigenbaum AL, Wolfe JH. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J Virol 2003; 77: 7034-7040. (Pubitemid 36666896)
42. Passini MA, Wolfe JH. Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector. J Virol 2001; 25: 12382-12392. (Pubitemid 33115910)
43. Rudolph D, Sterker I, Graefe G, Till H, Ulrich A, Geyer C. Visual field constriction in children with shunt-treated hydrocephalus. J Neurosurg Pediatr 2010; 6: 481-485.
44. Watson G, Bastacky J, Belichenko P, Buddhikot M, Jungles S, Vellard M et al. Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Therapy 2006; 13: 917-925.
45. Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 2010; 18: 1731-1735.
46. Gray SJ, Woodard KT, Samulski RJ. Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv 2010; 1: 517-534.
47. Jaffer FA, Vinegoni C, John MC, Aikawa E, Gold HK, Finn AV et al. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation 2008; 118: 1802-1809.
48. Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol 2007; 3: 668-677. (Pubitemid 47417706)
49. Maxwell D, Chang Q, Zhang X, Barnett EM, Piwnica-Worms D. An improved cell-penetrating, caspase-activatable, near-infrared fluorescent peptide for apoptosis imaging. Bioconjug Chem 2009; 20: 702-709.
50. Hyde D, de Kleine R, MacLaurin SA, Miller E, Brooks DH, Krucker T et al. Hybrid FMT-CT imaging of amyloid-beta plaques in a murine Alzheimer's disease model. Neuroimage 2009; 44: 1304-1311.
51. Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001; 12: 563-572.
52. Saftig P, Peters C, von Figura K, Craessaerts K, Van Leuvan F, De Strooper B. Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D. J Biol Chem 1996; 271: 27241-27244. (Pubitemid 26367274)
53. Bakowska JC, Di Maria MV, Camp SM, Wang Y, Allen PD, Breakefield XO. Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV reP(r) hybrid amplicon vector. Gene Therapy 2003; 10: 1691-1702. (Pubitemid 37069497)